end-stage heart failure
About
End-stage heart failure is the final stage of the development of various heart diseases (coronary heart disease, cardiomyopathy, valvular heart disease, hypertensive heart disease, etc.). The heart's blood pumping function is severely impaired and cannot meet the body's metabolic needs. Core dilemmas: ① Mature cardiomyocytes almost lose their ability to proliferate and cannot repair lost myocardial tissue through drugs;② Heart transplantation is the only radical cure, but donors are extremely scarce;③ Mechanical circulation support (LVAD) can be used as a bridge or endpoint treatment, but there is a risk of complications such as infection and thrombosis.
Features & Symptoms
- Complete failure of heart pumping function
- repeated hospitalization
- Severe edema, difficulty breathing
- Very poor response to drugs
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Xenotransplantation of heart (pig heart) | Genetically modified pig heart transplantation, the University of Maryland completed the world's first human trial in 2022, and the patient survived for 2 months. 2023-2024 Several surgeries were carried out one after another in 2000, providing new hope for patients with end-stage heart failure. | 临床试验 | $800K - $2.5M/次 |
| Stem cell myocardial regenerative therapy | iPSC-derived cardiomyocytes are injected or patched to repair myocardial scars. Multiple Phase I/II trials are ongoing. | Phase I/II | $200K - $600K/疗程 |
| Total artificial heart (TAH) | SynCardia Total Artificial Heart as a bridge therapy before heart transplantation or as an endpoint therapy for patients not suitable for transplantation. | 临床应用 | $300K - $800K/次 |
Prognosis
The 1-year mortality rate exceeds 50%, and the 5-year survival rate is less than 20%
Additional Notes
Notes: INTERMACS Classification: Patients with grade 1-2 should be evaluated for mechanical circulation support (LVAD) or heart transplantation as soon as possible;GDMT optimization: The drug therapy recommended in the guidelines (ARNI+ beta blockers +MRA+ SGLT2i) should be optimized to achieve the maximum tolerated dose; Device treatment: Patients with LVEF≤35% and QRS>150ms should be evaluated for ICD/CRT-D implantation; Water limit sodium limit: daily fluid intake <2 L, sodium intake <3 g; Exercise rehabilitation: Cardiac rehabilitation training under professional guidance can improve exercise tolerance and quality of life.; Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Research phase: Clinical trial. Prognosis: The 1-year mortality rate exceeds 50%, and the 5-year survival rate is less than 20%.
Frequently Asked Questions
What is end-stage heart failure?
End-stage heart failure is the final stage of the development of various heart diseases (coronary heart disease, cardiomyopathy, valvular heart disease, hypertensive heart disease, etc.). The heart's blood pumping function is severely impaired and cannot meet the body's metabolic needs. Core dilemmas: ① Mature cardiomyocytes almost lose their ability to proliferate and cannot repair lost myocardial tissue through drugs;② Heart transplantation is the only radical cure, but donors are extremely scarce;③ Mechanical circulation support (LVAD) can be used as a bridge or endpoint treatment, but there is a risk of complications such as infection and thrombosis.
What are the symptoms of end-stage heart failure?
Complete failure of heart pumping function,repeated hospitalization,Severe edema, difficulty breathing,Very poor response to drugs
How is end-stage heart failure treated?
Xenotransplantation of heart (pig heart): Genetically modified pig heart transplantation, the University of Maryland completed the world's first human trial in 2022, and the patient survived for 2 months. 2023-2024 Several surgeries were carried out one after another in 2000, providing new hope for patients with end-stage heart failure.; Stem cell myocardial regenerative therapy: iPSC-derived cardiomyocytes are injected or patched to repair myocardial scars. Multiple Phase I/II trials are ongoing.; Total artificial heart (TAH): SynCardia Total Artificial Heart as a bridge therapy before heart transplantation or as an endpoint therapy for patients not suitable for transplantation.
What is the prognosis for end-stage heart failure?
The 1-year mortality rate exceeds 50%, and the 5-year survival rate is less than 20%